Lixte Current Ratio from 2010 to 2025

LIXTW Stock  USD 0.05  0.0003  0.60%   
Lixte Biotechnology Current Ratio yearly trend continues to be fairly stable with very little volatility. Current Ratio is likely to outpace its year average in 2025. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
12.36
Current Value
12.97
Quarterly Volatility
7.62313335
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 19.6 K, Other Operating Expenses of 6.1 M or EBITDA of 3.9 K, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 1.06. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Lixte Biotechnology Holdings over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Lixte Biotechnology's Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 5.36 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Lixte Current Ratio Regression Statistics

Arithmetic Mean9.10
Geometric Mean5.36
Coefficient Of Variation83.75
Mean Deviation6.63
Median11.23
Standard Deviation7.62
Sample Variance58.11
Range23.7768
R-Value0.72
Mean Square Error30.24
R-Squared0.51
Significance0
Slope1.15
Total Sum of Squares871.68

Lixte Current Ratio History

2025 12.97
2024 12.36
2023 13.73
2022 14.08
2021 16.81
2020 24.15
2019 11.23

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Current Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Ratio 12.36  12.97 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.